MedTrace Logo

A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019（COVID-19）Pneumonia

NCT04880694 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-04-08

No results posted yet for this study

Summary

The study is a Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects with Severe Corona Virus Disease 2019（COVID-19）Pneumonia.

Conditions

  • Severe COVID-19 Pneumonia

Interventions

DRUG

STC3141

To receive continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.

DRUG

STC3141

To receive continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.

Sponsors & Collaborators

  • Trium Clinical Consulting

    collaborator INDUSTRY

  • Grand Medical Pty Ltd.

    lead INDUSTRY

Principal Investigators

  • James Pang, PhD · Grand Medical Pty Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2022-01-07
Completion
2022-01-07

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04880694 on ClinicalTrials.gov